J Breast Cancer.  2006 Sep;9(3):249-253. 10.4048/jbc.2006.9.3.249.

The Efficacy of Oral Combination Chemotherapy of 5'-DFUR and Cyclophosphamide for Metastatic Breast Cancer

• Park MH
• Yoon JH
• Jegal YJ

• KMID: 2286656
• DOI: http://doi.org/10.4048/jbc.2006.9.3.249

Abstract

PURPOSE
A sufficient response rate and good compliance are both important for instituting chemotherapy to treat metastatic breast cancer. Effective oral chemotherapy regimens have long been studied to improve patients' compliance. 5'-Deoxy-5-fluorouridine (5'-DFUR) is a prodrug of 5-fluorouracil (5-FU), which is known to be converted by thymidine phosphorylase (dThdPase). A recent preclinical study revealed that cyclophosphamide (CPA) upregulated dThdPase activity and especially in tumor cells. The purpose of this study was to examine the efficacy of long-term administration of 5'-DFUR/CPA for the patients suffering with metastatic breast cancer.
METHODS
Thirty four cases with metastatic breast cancer after curative surgery were enrolled in this study. All the patients had been previously exposed to standard chemotherapy such as CMF (CPA, methotrexate, and 5-FU) and CAF (CPA, doxorubicin, and 5-FU). All patients had distant metastasis such as in the bone, lung and liver. Daily treatment consisted of 5'-DFUR 800 mg and CPA 100 mg both were given orally. The treatment was continued for at least 24 weeks.
RESULTS
The mean age was 49 years and the treatment period ranged from 24 to 60 weeks. The response rate was 35.3%, while it was 26.5% for the patients with stable disease. The mean time to tumor progression was 36 weeks. A significant decrease in pain occurred in twenty patients (69%) with bone metastasis. The frequent adverse effects were leukopenia (32.4%) and gastrointestinal symptoms (20.4%). There was significant correlation between the rate of side effects and the duration of medication (p=0.010).
CONCLUSION
These findings show that oral administration of 5'-DFUR and CPA is well tolerated on an outpatient basis and it was proven to suppress tumor progression. So, an oral combination therapy with 5'-DFUR and CPA may be suitable for metastatic breast cancer.

Keyword

metastatic breast cancer; 5'-Deoxy-5-fluorouridine; Cyclophosphamide; Efficacy

MeSH Terms

Administration, Oral
Breast Neoplasms*
Breast*
Compliance
Cyclophosphamide*
Doxorubicin
Drug Therapy
Drug Therapy, Combination*
Fluorouracil
Humans
Leukopenia
Liver
Lung
Methotrexate
Neoplasm Metastasis
Outpatients
Thymidine Phosphorylase
Cyclophosphamide
Doxorubicin
Fluorouracil
Methotrexate
Thymidine Phosphorylase

Reference

1. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H, et al. Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull. 1983. 31:175–178.

2. Fujita H, Ogawa K, Nakagawa H. Phamacokinetics of 5'-deoxy-5-fluorouridine (5'-DFUR) by oral administration. Nippon Gan Chiryo Gakkai shi. 1983. 18:916–926.

3. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, et al. Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) on patients with malignant cancer: Multi-institutional cooperative study. Gan To Kagaku Ryoho. 1985. 12:2044–2051.

4. Taguchi T, Terasawa T, Abe O, Yoshida Y, Tominaga T, Ogawa N, et al. A comparative study between 5'-DFUR and tegafur in recurrent breast cancer. Gan To Kagaku Ryoho. 1985. 12:2052–2060.

5. Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine. Eur J Cancer. 1980. 16:427–432.

6. Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H, Yagi Y. Comparative studies on the immuno-suppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gann. 1980. 71:190–196.

7. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Tanaka Y, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer. 1999. 83:127–134.

8. Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsquent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades. Ann Oncol. 2002. 13:197–207.

9. Nagai S, Toi M, Kuroi K, Hayashi K, Tomnaga T. Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline. Gan To Kagaku Ryoho (Jpn J Cancer Chemother). 1999. 26:2037–2042.

10. Abe O, Izuo M, Enomoto K, Kubo K, Koyama H, Sakai K, et al. Combination chemotherapy of cyclophosphamide, adriamycin and 5-fluorouracil(CAF) in advanced and recurrent breast cancer. Gan To Kagaku Ryoho (Jpn J Cancer Chemother). 1982. 9:866–873.

11. Koyama H, Nishizawa Y, Noguchi S, Yamamoto H, Miyauchi K, Inaji H, et al. Combination therapy with 5'-DFUR and MPA as a second line treatment for advanced/recurrent breast cancer. Nippon Gan Chiryo Gakkai Shi. 1990. 25:655–661.

12. Ogawa Y, Ishikawa T, Chung SH, Ikeda K, Takashima T, Onoda N, et al. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res. 2003. 23:3453–3457.

13. Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, et al. Randomized controlled trial comparing oral doxifluridine plus oral cyclophophamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. J Clin Oncol. 2003. 21:991–998.

14. Hori T, Kodama H, Nishimura S, Hatano T, Okamura R, Fujii K, et al. A randomized study comparing oral and standard regimens for metastatic breast cancer. Oncol Rep. 2001. 8:1067–1071.